Ozempic & Zepbound Lawsuits Rise: 2,000+ Claim Side Effects

The popularity of weight-loss drugs like Ozempic and Zepbound has exploded, but a growing number of patients are now coming forward with serious health concerns. Over 2,000 lawsuits have been filed against the manufacturers, Novo Nordisk and Eli Lilly, alleging that these widely used GLP-1 drugs caused dangerous and potentially permanent side effects.

Allegations of Undisclosed Dangers

These lawsuits, now consolidated in a Pennsylvania federal court, claim that the drugmakers failed to adequately warn patients about the severe risks associated with these medications. The core of the legal challenges revolves around allegations that patients developed gastroparesis, a condition often referred to as stomach paralysis.

Beyond gastroparesis, plaintiffs are reporting other severe gastrointestinal issues, including intestinal obstructions, persistent vomiting, and gallbladder disease. Some patients have also linked their use of these drugs to vision loss, specifically non-arteritic anterior ischaemic optic neuropathy. While medical experts acknowledge that GLP-1 drugs slow stomach emptying, the extent and severity of these reported complications are raising significant concerns.

Regulatory Updates and Company Responses

In response to these growing concerns, regulatory bodies have begun to act. The FDA updated its safety label for Zepbound in February 2025 to include warnings about ileus, a serious intestinal blockage. Similar updates have been made to the labels for Ozempic and Mounjaro. Despite these developments, both Novo Nordisk and Eli Lilly maintain that their drug information meets federal standards and deny any wrongdoing.

The litigation is still in its early stages, with the discovery phase underway. Analysts predict that the first test cases might not go to trial until 2026, meaning this legal battle could be a lengthy one. Meanwhile, Novo Nordisk has also taken legal action, filing lawsuits against U.S. pharmacies accused of selling unapproved compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy.